Nearly $300 million in medtech financings for March 2011

Financings in medical technology for the month of March 2011 reached almost $300 million, well off the blistering pace of $656 million financings in February, but a solid influx of money to medtech nonetheless.

The top financing for the month are shown below, headed by CardioDx’s $57 million funding.

CardioDx Inc. has raised $57.49 of a planned $78.33 million round of funding (Gene expression test to predict coronary artery disease)
Tengion, Inc., has raised $31.35 million from Medtronic and other investors (Tissue-engineered organs)
NovaShunt AG has raised CHF 23.7 million ($25 million) in a Series B financing (Implantable abdominal pump for removal of ascites in liver cirrhosis, certain cancers and congestive heart failure)
Amedica Corp. has raised $22.125 million of a planned $30 million round of financing (Spine surgery and orthopedic technologies)
Retinal Implant AG has raised $18 million in a new round of funding (Electronic retinal implant to restore vision)
Veran Medical Technologies, Inc., has raised $15 million in funding (Minimally invasive technologies for interventional oncology treatment)

The complete list of fundings for March is at link.

Author

PatrickDriscoll

I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses.Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.

View all posts by PatrickDriscoll